Get the Stockscreener App
38.56
5.44%
-2.22
After Hours:
38.68
0.12
+0.31%
Royalty Pharma Plc stock is traded at $38.56, with a volume of 9.33M.
It is down -5.44% in the last 24 hours and up +6.81% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$40.78
Open:
$38.625
24h Volume:
9.33M
Relative Volume:
2.30
Market Cap:
$16.67B
Revenue:
$2.31B
Net Income/Loss:
$1.66B
P/E Ratio:
16.79
EPS:
2.297
Net Cash Flow:
$827.02M
1W Performance:
+2.72%
1M Performance:
+6.81%
6M Performance:
+17.74%
1Y Performance:
+45.40%
1-Day Range:
$38.39
$40.10
1-Week Range:
$36.03
$41.24
52-Week Range:
$24.05
$41.24
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
38.56 | 17.42B | 2.31B | 1.66B | 827.02M | 2.297 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-25 | Initiated | Goldman | Buy |
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Will Royalty Pharma plc (RPD) stock maintain strong growthQuarterly Portfolio Summary & Technical Confirmation Trade Alerts - newser.com
Applying chart zones and confluence areas to Royalty Pharma plc2025 Winners & Losers & Real-Time Buy Signal Alerts - newser.com
Quantitative breakdown of Royalty Pharma plc recent moveJuly 2025 Pullbacks & Stock Timing and Entry Methods - newser.com
Historical volatility pattern of Royalty Pharma plc visualizedJuly 2025 Intraday Action & Low Drawdown Investment Strategies - newser.com
Is Royalty Pharma plc (RPD) stock attractive post correctionChart Signals & Daily Momentum Trading Reports - newser.com
Can Royalty Pharma plc stock rebound after recent weaknessAnalyst Downgrade & Weekly Top Gainers Alerts - newser.com
Analyzing net buyer seller activity in Royalty Pharma plcTrade Ideas & Intraday High Probability Setup Alerts - newser.com
Why retail investors pile into Royalty Pharma plc stock2025 Investor Takeaways & Daily Technical Stock Forecast Reports - newser.com
(RPRX) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Will Royalty Pharma plc (RPD) stock hit Wall Street targetsQuarterly Trade Review & Growth Focused Entry Reports - newser.com
Achmea Investment Management B.V. Invests $1.23 Million in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Announces Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Published on: 2025-11-07 09:50:08 - newser.com
Royalty Pharma Plc Hits New 52-Week High of $38.09 - Markets Mojo
C WorldWide Group Holding A S Has $22.60 Million Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Position Increased by Bryn Mawr Trust Advisors LLC - MarketBeat
Royalty Pharma raises 2025 top line guidance to $3.2B–$3.25B amid strong portfolio expansion - MSN
Is Royalty Pharma plc stock a safe investment in uncertain marketsWeekly Profit Report & AI Forecast Swing Trade Picks - newser.com
Why analysts remain bullish on Royalty Pharma plc stockQuarterly Investment Review & Capital Efficient Trade Techniques - newser.com
Is Royalty Pharma plc reversing from oversold territoryPortfolio Performance Summary & Consistent Growth Equity Picks - newser.com
Goldman Sachs raises Royalty Pharma stock price target to $45 on strong results By Investing.com - Investing.com South Africa
Goldman Sachs raises Royalty Pharma stock price target to $45 on strong results - Investing.com Australia
Royalty pharma to buy its external manager, announces $3B share buyback - MSN
What’s the recovery path for long term holders of Royalty Pharma plc2025 Performance Recap & Step-by-Step Swing Trade Plans - newser.com
Published on: 2025-11-06 05:49:05 - newser.com
Royalty Pharma (RPRX) PT Raised to $45 at Goldman Sachs - StreetInsider
How Royalty Pharma plc (RPD) stock performs in easing cyclesPortfolio Return Summary & Safe Entry Momentum Tips - newser.com
Royalty Pharma Reports Strong Q3 2025 Results - TipRanks
Royalty Pharma Q3 2025 slides: Portfolio receipts up 11%, guidance raised - Investing.com Nigeria
Why Royalty Pharma plc (RPD) stock could outperform next year2025 AllTime Highs & Stepwise Trade Signal Implementation - newser.com
Why Royalty Pharma plc (RPD) stock could rally stronglyJuly 2025 Breakouts & Reliable Volume Spike Alerts - newser.com
Royalty Pharma (RPRX) Beats Q3 Earnings and Revenue Estimates - sharewise.com
Royalty Pharma (RPRX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - sharewise.com
Royalty Pharma’s Q3 2025 Earnings Call Highlights - TipRanks
Royalty Pharma (RPRX) Earnings Soar 52% as Margin Surge Challenges Bearish Narratives - Yahoo Finance
Does Royalty Pharma plc qualify in momentum factor screeningMarket Performance Report & Daily Risk Controlled Trade Plans - newser.com
Is Royalty Pharma plc stock supported by strong fundamentalsJuly 2025 Macro Moves & Scalable Portfolio Growth Methods - fcp.pa.gov.br
Can Royalty Pharma plc stock beat analyst upgradesGlobal Markets & Long-Term Safe Investment Plans - newser.com
Royalty Pharma's Strong Portfolio Growth and Manager Acquisition Boost Long-Term Outlook - Morningstar
Is Royalty Pharma plc (RPD) stock undervalued historicallyJuly 2025 Opening Moves & Target Return Focused Stock Picks - Fundação Cultural do Pará
Royalty Pharma stock hits 52-week high at 38.01 USD By Investing.com - Investing.com Australia
Royalty Pharma plc Announces Earnings Guidance for the Full Year 2025 - MarketScreener
Cytokinetics Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire Inc.
Royalty Pharma Raises Earnings Outlook After Beating Estimates - Finimize
Royalty Pharma (NASDAQ:RPRX) Reaches New 12-Month HighWhat's Next? - MarketBeat
Royalty Pharma PLC (RPRX) Q3 2025 Earnings Call Highlights: Strong Portfolio Growth and ... By GuruFocus - Investing.com Canada
Earnings call transcript: Royalty Pharma Q3 2025 reports robust growth By Investing.com - Investing.com Australia
Royalty Pharma Q3 2025 Earnings Call Transcript - MarketBeat
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.62%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):